货号价格

SOT-HM401B-100μg / 询价

SOT-HM401B-500μg / 询价

SOT-HM401B-500μgx2 / 询价

Biotinylated Human SOST/Sclerostin Protein

产品信息(Product Info)
表达区间及表达系统(Source)

Recombinant Biotinylated Human SOST/Sclerostin Protein is expressed from HEK293 with His and Avi tag at the N-Terminus.
It contains Gln24-Tyr213 [Accession | Q9BQB4-1].

分子量大小(Molecular Weight)

The protein has a predicted MW of 24.2 kDa. Due to glycosylation,the protein migrates to 28-40 kDa based on Bis-Tris PAGE result.

纯度(Purity)

> 95% as determined by Bis-Tris PAGE

内毒素(Endotoxin)

Less than 1EU per μg by the LAL method.

制剂(Formulation)

Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.

重构方法(Reconstitution)

Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.

存储(Storage)

-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

产品数据(Assay Data)
Bis-Tris PAGE

Biotinylated Human SOST on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

ELISA Data

Immobilized Anti-SOST Antibody at 1μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Human SOST, His Tag with the EC50 of 9.6ng/ml determined by ELISA (QC Test).

ELISA Data

Immobilized Biotinylated Human SOST, His Tag at 5μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml). Dose response curve for Human LRP-6, mFc Tag with the EC50 of 8.7ng/ml determined by ELISA.

背景(Background)

SOST, also known as sclerostin, is a member of the cerberus/DAN family, a group of secreted glycoproteins characterized by a cysteine-knot motif. SOST is negative regulator of bone growth that acts through inhibition of Wnt signaling and bone formation.

分子别名(Synonyms)

sclerostin; SOST; VBCHsclerosteosis; CDD; DAND6; SOST1; VBCH

文献(References)

(1)Claire M N , Patton D , Hayes J S. Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges[J]. Journal of Osteoporosis, 2016, 2016:1-22.